Arcturus Therapeutics
Yahoo Finance • yesterday
Cathie Wood's ARK boosts Palantir, Tesla, Roninhood bets; cuts semiconductor exposure
Joe Raedle Cathie Wood’s ARK Invest funds executed a broad rotation across technology, healthcare, and industrial names during the last week while markets remained volatile over broader geopolitical tensions between the U.S. and Iran. Bu... Full story
Yahoo Finance • 20 days ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
It seems as if Cathie Wood can't have nice things. The founder and CEO of the Ark Invest family of aggressive-growth exchange-traded funds (ETFs) had a market-thumping performance in 2020, only to fall short for a few years. She came throu... Full story
Yahoo Finance • 22 days ago
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
Last week was challenging for most investors. The three major market indexes moved lower for the fourth consecutive week. Growing investing icon Cathie Wood -- the founder, CEO, and primary stock picker of Ark Invest's family of ETFs -- ha... Full story
Yahoo Finance • last month
Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 MANAGEMENT VIEW * CEO Joseph Payne provided an update on the ARCT-032 and ARCT-810 programs, stating the ARCT-032 Phase II trial is progressing with higher dose... Full story
Yahoo Finance • last month
Arcturus Therapeutics GAAP EPS of -$2.40 misses by $0.24, revenue of $82M misses by $8.47M
* Arcturus Therapeutics press release [https://seekingalpha.com/pr/20422782-arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2025-financial-results-and] (ARCT [https://seekingalpha.com/symbol/ARCT]): FY GAAP EPS of -$2.40 m... Full story
Yahoo Finance • 2 months ago
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The seventeenth stock on our list is Arcturus Therapeutics Holdings Inc. TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy... Full story
Yahoo Finance • 4 months ago
Cathie Wood tilts toward Robinhood, Bitcoin ETFs, trims Tesla, Iridium
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and sate... Full story
Yahoo Finance • 4 months ago
Cathie Wood Dumps Tesla Again, Pours Millions Into This Tech Gaint
This article first appeared on GuruFocus. Cathie Wood's ARK Invest funds shifted positions Monday, increasing stakes in Chinese tech giant Baidu (BIDU) while trimming exposure to Tesla (NASDAQ:TSLA). The ARK Innovation ETF (ARKK) purchas... Full story
Yahoo Finance • 5 months ago
Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 MANAGEMENT VIEW * CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "... Full story
Yahoo Finance • 6 months ago
Arcturus cut to Neutral at Citi on data for mRNA candidate
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) traded lower on Friday after Citi downgraded the San Diego, California-based biotech, citing m... Full story
Yahoo Finance • 6 months ago
Coinbase, eBay upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Citizens JMP upgraded eBay (EBAY) to O... Full story
Yahoo Finance • 6 months ago
Trending tickers: Tesla, IonQ, IBM, Arcturus and Unilever
Tesla (TSLA) Tesla reported a rebound in quarterly revenue overnight, marking the end of two consecutive periods of decline. However, profits fell sharply as higher costs and lower vehicle prices weighed on the results. The weaker-than-ex... Full story
Yahoo Finance • 6 months ago
Noteworthy Thursday Option Activity: AKRO, DHI, AFRM
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Akero Therapeutics Inc (Symbol: AKRO), where a total of 8,313 contracts have traded so far, representing approximately 831,300 und... Full story
Yahoo Finance • 6 months ago
Cathie Wood's Ark Invest weekly recap: adds Chinese tech names, Intellia Therapeutics
ARK Invest CEO Cathie Wood recently pointed out that the AI space is ruled by “big four” players: OpenAI, Anthropic, Elon Musk’s xAI, and Google’s (GOOG [https://seekingalpha.com/symbol/GOOG]) Gemini, describing the competition among these... Full story
Yahoo Finance • 8 months ago
Meta, Goldman Sachs lead Tuesday's market cap stock movers
Tuesday’s market has seen notable shifts with several stocks making significant intra-day movements. Mega-cap stocks like Facebook Inc (NASDAQ:META) and Goldman Sachs Group (NYSE:GS) are experiencing upward trends, while large-cap stoc... Full story
Yahoo Finance • 8 months ago
Top movers in Tuesday's session
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story
Yahoo Finance • 8 months ago
Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates
Investing.com - Wells Fargo lowered its price target on Arcturus Therapeutics (NASDAQ:ARCT) to $42.00 from $45.00 on Tuesday while maintaining an Overweight rating on the stock. The biotech company, currently valued at $309 million, has sh... Full story
Yahoo Finance • 8 months ago
Arcturus outlines pivotal trial plans and advances CF and OTC programs with regulatory meetings expected in 2026
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 MANAGEMENT VIEW * CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5-milligram cohort... Full story
Yahoo Finance • 8 months ago
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates
Investing.com - Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported second quarter EPS of $-0.34, $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $28.3M versus the consensus estimate of $191.77M.... Full story
Yahoo Finance • 8 months ago
Arcturus Therapeutics Q2 2025 Earnings Preview
* Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) is scheduled to announce Q2 earnings results on Monday, August 11th, after market close. * The consensus EPS Estimate is -$0.87 [https://seekingalpha.com/symb... Full story
